ALSPW Spineway SAS

Participation to Lyon Pole Bourse - investors forum

Participation to Lyon Pole Bourse - investors forum

Press release        Ecully, September 22, 2022 -18h



Spineway participates to the Lyon Pôle Bourse Forum

SPINEWAY, specialized in the design, manufacturing and marketing of spine implants and surgical instruments, announces its participation to the Lyon Pôle Bourse Regional Values Forum, on Wednesday, September 28, 2022, at the Palais de la Bourse de Lyon, Esplanade François Mitterrand, in Lyon.

        

This investor forum dedicated to listed companies based in the Auvergne-Rhône-Alpes and Bourgogne-Franche-Comté regions, will be an opportunity for Spineway to meet investors and financial analysts through "one-to-one" or "one-to-few" meetings, either face-to-face or via videoconference.

                

The Lyon Regional Stock Exchange Forum brings together more than 100 professional investors with the managers of some thirty large, mid and small caps. The 2021 edition of the forum has enabled 550 rich and fruitful meetings.

Next Appointment :

October 14, 2022: 3rd quarter revenues

SPINEWAY IS ELIGIBLE FOR PEA-SME

Find all the information about Spineway on

Ce communiqué de presse est rédigé en anglais et en français. En cas de divergence, la version française prévaudra.

Spineway designs, manufactures and markets innovative surgical implants and ancillary products (instruments) for the treatment of severe spine pathologies.

Spineway has a worldwide network of more than 50 independent distributors and generates 90% of its revenues from exports.

Spineway, eligible for FCPI funds, has received the OSEO Excellence label since 2011 and is a winner of the Deloitte Fast 50 trophy (2011). INPI Rhône Alpes Patent Policy Award (2013) - INPI Talent Label (2015).

ISIN : FR001400BVK2- ALSPW        

Contacts :





SPINEWAY



Shareholder Line

Open Tuesday to Thursday (10am-12pm)

0806 70 60 60






Eligible PEA / PME



ALSPW



Euronext Growth









AELIUM



Finance & Communication



Investor Relations

Solène Kennis

spineway@aelium.fr

Attachment



EN
22/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch